Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.

Cancer discovery - 1 Apr 2016

Ogiwara Hideaki, Sasaki Mariko, Mitachi Takafumi, Oike Takahiro, Higuchi Saito, Tominaga Yuichi, Kohno Takashi

Abstract excerpt

UNLABELLED: Loss-of-function mutations in the CBP/CREBBP gene, which encodes a histone acetyltransferase (HAT), are present in a variety of human tumors, including lung, bladder, gastric, and hematopoietic cancers. Consequently, development of a molecular targeting method capable of specifically killing CBP-deficient cancer cells would greatly improve cancer therapy. Functional screening of synthetic-lethal genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Assembly and Disassembly
Share to CREB-Binding Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to E1A-Associated p300 Protein

Share to G1 Phase Cell Cycle Checkpoints

Share to Heterografts

Share to Histone Acetyltransferases

Share to Proto-Oncogene Proteins c-myc

Share to Synthetic Lethal Mutations

Source

Identifiers

PMID: 26603525
DOI: 10.1158/2159-8290.CD-15-0754

Genes

MYC
CREBBP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.PMID 26603525Read ↗

Dysregulation of the p300/CBP histone acetyltransferases in human cancer.Semantic proximity Read ↗

Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer.Semantic proximity Read ↗

Genetic mutations and inhibitors of p300 and CBP.Semantic proximity Read ↗

Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphomaSemantic proximity Read ↗

Characteristics of anticancer activity of CBP/p300 inhibitors – Features of their classes, intracellular targets and future perspectives of their application in cancer treatmentSemantic proximity Read ↗

CBP/p300 acetyltransferase activity in hematologic malignancies.Semantic proximity Read ↗

p300/CBP and cancerSemantic proximity Read ↗

Essentiality of <i>CREBBP</i> in <i>EP300</i> truncated B-cell lymphoma revealed by genome-wide CRISPR-Cas9 screenSemantic proximity Read ↗

PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation.Semantic proximity Read ↗

Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular CarcinomaSemantic proximity Read ↗

Targeting the p300/CBP Axis in Lethal Prostate CancerSemantic proximity Read ↗

EP300 deficiency leads to chronic replication stress mediated by defective replication fork protection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.